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Epidermolysis bullosa acquisita (EBA) is an orphan autoimmune disease. Patients
with EBA suffer from chronic inflammation as well as blistering and scarring of
the skin and mucous membranes. Current treatment options rely on non-specific
immunosuppression, which in many cases, does not lead to a remission of treatment.
Hence, novel treatment options are urgently needed for the care of EBA patients.
During the past decade, decisive clinical observations, and frequent use of pre-clinical
model systems have tremendously increased our understanding of EBA pathogenesis.
Herein, we review all of the aspects of EBA, starting with a detailed description of
epidemiology, clinical presentation, diagnosis, and current treatment options. Of note,
pattern analysis via direct immunofluorescence microscopy of a perilesional skin lesion
and novel serological test systems have significantly facilitated diagnosis of the disease.
Next, a state-of the art review of the current understanding of EBA pathogenesis,
emerging treatments and future perspectives is provided. Based on pre-clinical model
systems, cytokines and kinases are among the most promising therapeutic targets,
whereas high doses of IgG (IVIG) and the anti-CD20 antibody rituximab are among the
most promising “established” EBA therapeutics. We also aim to raise awareness of EBA,
as well as initiate basic and clinical research in this field, to further improve the already
improved but still unsatisfactory conditions for those diagnosed with this condition.
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EPIDEMIOLOGY
The incidence of most autoimmune blistering diseases is increasing. Although the incidence of
epidermolysis bullosa acquisita (EBA) is not known in detail, it is estimated to be rare. The most
common autoimmune subepidermal blistering disease, bullous pemphigoid (BP), is reported to
have an annual estimated incidence between 2.4 and 21.7 per million (1, 2). By contrast, the
estimated incidence of EBA is reported to be<0.5 per million (3–7). In South Korea, the incidence
and prevalence of EBA is estimated to be higher than that of previous reports (8), but the exact
epidemiologic data have not been surveyed. In Germany, the EBA prevalence has recently been
determined to be 2.8 cases per million (9). This ethnical difference may be due to the reported
association of EBA with the human leukocyte antigen (HLA) class II (10–12). EBA occurs at any
age; the onset age in previous case reports exhibit a wide range from 1 to 94 years old (13–15). Two
onset age peaks are reported; the second and seventh decades (9).
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CLINICAL PRESENTATION
Several clinical EBA manifestations have been described: (i) the
classical/mechano-bullous form and (ii) the non-classical/non-
mechano-bullous forms (16). The latter includes BP-like EBA
that meets the clinical criteria of both EBA and BP, mucous
membrane (MM)-EBA that is clinically defined by predominant
mucous membrane lesions, IgA-EBA that is defined by the
IgA class of immune deposits, and Brunsting-Perry-like EBA
(Figure 1). Few patients may have a MM-IgA-EBA. The relative
frequencies of these different clinical forms of EBA reported
in the few series in the literature (17–21) depend on the
morphological and/or serological diagnostic means available to
the authors (Table 1). The two most common presentations of
EBA are the classical/mechano-bullous and the BP-like forms.
It should be recognized that in an individual EBA patient,
clinical presentation may change over time. Notably, patients
may switch from a BP-like form to a classical/mechanobullous
form or when mucous membrane lesions appear secondarily
from a BP-like form to a MM-EBA (22).
Regardless of the clinical form, patients present with
cutaneous-mucous fragility, which is easily suspected when the
lesions are on trauma-prone areas. Bullous lesions or erosions
that are linear or with angular contours can also provide evidence
of this fragility (Figure 2). Questioning the patient can confirm
that bullous lesions appear immediately or a few hours after a
trauma which can be minimal. This fragility can be quantified
by applying an analogical visual scale. Because in EBA the
subepidermal cleavage is deep on the dermal side of the basement
membrane zone (BMZ), the cutaneous blisters can persist for a
Abbreviations: 17-AAG, tanespimycin; 17-DMAG, 17-imethylaminoethylamino-
17-demethoxygeldanamycin; ABQOL, autoimmune bullous disease quality of
life; AIBD, autoimmune blistering disease; AKT, protein kinase B; APC, antigen-
presenting cell; AZA, azathioprine; BLT, leukotriene B4 receptor; BMZ, basement
membrane zone; BP, bullous pemphigoid; C, complement factor; CARD9,
caspase recruitment domain-containing protein 9; CD, cluster of differentiation;
CDNP, cell-derived nanoparticles; COL, collagen; CPA, cyclophosphamide;
CR, complete remission; CSA, cyclosporine; CXCR, CXC-chemokin receptor;
DDS, diaminodiphenyl sulfone; DEJ, dermal-epidermal junction; DIF, direct
immunofluorescence; DMF, dimethylfumarate; EBA, epidermolysis bullosa
acquisita; ECP, extracorporeal photochemotherapy; ELISA, enzyme-linked
immunosorbent assay; EndoS, endoglycosidase S; ERK, extracellular signal-
regulated kinase; FcgR, Fc gamma receptor; FcRn, neonatal Fc receptor; Flii,
flightless I; FOAM, fluorescent overlay antigen mapping; G0, agalactosylated
antibodies; GM-CSF, granulocyte-macrophage colony-stimulating factor; HLA,
human leukocyte antigen; Hsp, heat-shock protein; i.p., intraperitoneal; IA,
immunoadsorption; IC, immune complexes; IEM, immunoelectron microscopy;
IFN, interferon; Ig, immunoglobulin; IIF, indirect immunofluorescence
microscopy; IL, interleukin; IVIG, high-dose intravenous immunoglobulin;
JAK2, janus kinase 2; LAD, linear IgA bullous disease; LTB4, leukotriene B4;
MHC, major histocompatibility complex; MIP1a, macrophage inflammatory
protein1a; MM-EBA, mucous membrane EBA; MMF, mycophenolate mofetil;
MMP, mucous membrane pemphigoid; MMPs, matrix metalloproteases; MTX,
methotrexate; NADPH, nicotinamide adenine dinucleotide phosphate; NC,
non-collagenous; NCF1, neutrophil cytosolic factor 1; NKT, natural killer T cells;
p.o., per os; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PR, partial
remission; RORa, retinoid-related orphan receptor-alpha; ROS, reactive oxygen
species; RTX, rituximab; SLE, systemic lupus erythematodes; SSS, NaCl-split
skin; SYK, Spleen tyrosine kinase; TABQOL, treatment-based autoimmune
bullous disease quality of life; Th, T-helper; TNF-α, tumor necrosis factor α; Treg,
regulatory T cells; Trem1, triggering receptor expressed on myeloid cells-1.
FIGURE 1 | Diagram of different clinical forms of EBA. LAD, linear IgA disease.
MMP, mucous membrane pemphigoid; EBA, epidermolysis bullosa acquisita;
MM-EBA, mucous membrane EBA.
long time, collapsing and becoming flaccid before their rupture;
they can also be haemorrhagic.
CLASSICAL/MECHANO-BULLOUS EBA
Two cases of an adult-onset, acquired blistering disease
resembling patients with hereditary dystrophic epidermolysis
bullosa were reported by Elliott (23). Other similar cases were
described in early decades of the twentieth century (24, 25). The
first to actually coin the term “epidermolysis bullosa acquisita”
was probably Hundley and Smith (26). A landmark paper by
Roenigk and colleagues was published in 1971, who described
three new cases of EBA, reviewed the world literature and
proposed the first diagnostic criteria for classical/mechano-
bullous EBA (27).
The criteria of Roenigk were modified once immunological
tests for EBA diagnosis had been developed. Advanced
clinical criteria of the classical/mechanobullous form have been
published in 2017 (16). Current clinical diagnostic criteria for
the classical/mechanobullous form are skin fragility, blisters, or
erosions on non-inflamed or scarred skin, scarring and milium
formation, preferably located at trauma-prone sites and the
extensor skin surface (dorsal hands, elbows, knees, Achilles
tendon, feet) with possible nail dystrophy and scarring alopecia
(Figure 2). Fibrosis of the hands and fingers leading to a
mitten-like deformity may occur in patients with severe disease
reminiscent of hereditary dystrophic epidermolysis bullosa.
Mucosal involvement may also occur, but it is not predominant.
BP-LIKE EBA
BP-like form of EBA was first described by Gammon et al.
(28). This occurred shortly after the demonstration by Nieboer
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TABLE 1 | Clinical variants of EBA in the series of the literature.




























































a2 patients had the mixed form, b1 had a prurigo-like form, c11 had mucous membrane-EBA, including 2 with isolated IgA deposits.
et al. (29) and Yaoita et al. (30) that EBA autoantibodies are
deposited in the anchor fibrils zone, which allowed for a definite
diagnosis by immunoelectron microscopy (IEM), even though
the clinic was (based on the criteria by Roenigk) atypical. Indeed,
patients with a BP-like form of EBA have generally profuse skin
lesions suggestive of a BP in some areas and an EBA in others
(17, 31, 32). The patients have pruritus, tense bullae and erosions
on inflamed erythematous or urticarial skin as well as trauma-
induced bullous lesions surrounded by normal skin (Figure 2).
The lesions are on the trunk and folds but also on limb extensor
areas and distal extremities. The face can be affected. Mucosal
involvement is also possible, but it is not predominant. Finally,
lesions heal most often leaving atrophic scars and milia cysts as
in the mechanobullous form.
MM-EBA
The high frequency of mucosal lesions in EBA, in particular
tongue and lip involvement, was highlighted by Dahl (33).
Currently, MM-EBA cases are defined as EBA that mainly
affects mucous membranes with a squamous epithelium (16,
33–35), such as the mucous membrane of the mouth,
pharynx, esophagus, epiglottis, conjunctiva, genitalia, anus, and
respiratory tract in malpighian metaplasia, especially the trachea
and bronchi. Only one of these sites can be involved and
remain so for a long time before a second localization appears
in the case of inadvertent discontinuation of the treatment, a
decrease in dose or no treatment (36). These cases are frequently
misdiagnosed.
As on the skin, bullous lesions of mucous membranes rupture
late in MM-EBA. Thus, intact blisters are frequently seen
on mucous membranes in comparison to mucous membrane
pemphigoid (MMP), in which they are rare (Figure 2). The
erosions on the mucous membranes are similar in MM-EBA
and classical MMPs, except in the esophagus where they can be
linear, caused by mucous membrane fragility and the passage
of the fibroscope (37). The cicatricial lesions (atrophic scars,
synechiae, and stenosis) are identical inMM-EBA andMMP. The
cicatricial lesions have mild consequences in the mouth, genitals
and anus, but cause severe impairment in the esophagus, larynx,
trachea, bronchi, and conjunctiva, which dictate more aggressive
treatment and multidisciplinary management.
Esophageal stenosis, usually as a web located at the upper
esophagus, causes the most severe damage to the esophagus.
Esophageal stenosis causes dysphagia, weight loss and, at worst,
malnutrition and/or false routes and pulmonary infection (34,
36–50).
Severe lesions at the nose and throat are perforation of the
nasal septum and/or stenosis of nostrils, choanal, pharynx, and
larynx (39, 51–53). Involvement of the trachea and bronchi may
also rarely occur (51, 54). Scarring of the larynx or trachea are
potentially life-threatening because this may lead to asphyxiation
if tracheostomy is not performed. In general, mucous membrane
lesions in EBA patients are, however, asymptomatic in 30% of
cases (51).
Few case reports and small series of ocular involvement in
EBA have been reported (13, 33, 34, 55–64). Patients presented
the involvement of at least two other sites. Interestingly, in MM-
EBA, immune deposits of IgA are present in half of the cases
and the only Ig class in a third. Patients displayed a fibrosing
conjunctivitis that might worsen and eventually cause blindness.
The frequency of esophageal, nasal and throat, and
conjunctival involvement was, respectively, 6, 11, and 25%
of 39 EBA cases in a French series (65). Bladder involvement has
also been reported in one case (66).
In addition to MM-EBA, the involvement of mucous
membranes in “skin-predominant” EBA is common (34). Hence,
after the diagnosis of EBA, an interdisciplinary approach is
needed for both diagnosis and treatment.
IGA-EBA
Currently, IgA-EBA is defined as an EBA that presents with
linear IgA deposits at the BMZ. IgA-EBA may resemble linear
IgA bullous disease with erythematous cutaneous arciform
lesions and a few scars and milium cysts, in particular in
children. However, it IgA-EBA may also develop into a more
severe clinical manifestation, especially with scarring at mucosal
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FIGURE 2 | Different clinical forms of EBA. All patients were documented at the first visit in a center for auto-immune bullous disease. (Left) Patient with a
classical/mechanobullous form of EBA: lesions are preferably localized to the extensor skin surfaces and trauma-prone sites, i.e., dorsal hands knees elbows and
ankles. Tense or flaccid bullous lesions are surrounded by non-inflamed skin; erosions are covered or not by crusts; one erosion with angular contours had been
induced by adhesive plaster; old lesions have healed with milium formation and/or are atrophic papery scar. (Middle) Patient with a BP-like form of EBA, with little
blistering: urticarial plaques with small or large bullous lesions as in BP, but location of lesions on extensor areas of limbs, hands and scalp, and scars and extensor
areas of the face (not shown) and limbs (atypical for BP). (Right) Patient with a BP-like form of EBA, with extensive blistering: bullous lesions and erosions on
erythematous skin in flexural areas of limbs (tight and arm) as in BP but also bullous lesions and erosions on normal skin and involvement of extensor area of the limbs
and scalp, atypical for a BP involvement of the scalp (not shown) and both flexural and extensor areas of limbs extremities with bullous lesions and erosions on
erythematous but also normal skin. The tongue and the lips are the most frequent sites of mucosal lesions in all EBA variants. Other mucosal lesions (not shown) are
possible regardless of the variant of EBA The involvement of nasal and buccal mucous membrane are visible in all EBA variants.
sites, as reported in 30% of the 82 cases in the Vodegel
literature review, including 4% with severe ocular involvement
(16, 19, 67, 68).
BRUNSTING-PERRY TYPE EBA
Patients with Brunsting-Perry type EBA present only cutaneous
lesions, without erythematous or urticarial plaques, which
predominate in the head and neck and heal leaving very atrophic
scars. Review of seven of the eight cases reported in the literature
has recently been published by Asfour et al. (69–76).
NON-INFLAMMATORY VS.
INFLAMMATORY FORMS OF EBA
The definition of inflammatory and non-inflammatory forms of
EBA varies with the authors in the literature (17–21): (i) for most
of them but one, the non-inflammatory form of EBA overlays
the classical/non-mechano-bullous form; (ii) Buijsrogge et al.
included the Brunsting-Perry like type in the mechano-bullous
phenotype (19); (iii) for Briggaman et al. (17) who were the first
to describe the inflammatory form of EBA, and for Kim et al.
(18), the inflammatory form of EBA is synonymous to the BP-like
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form; (iv) for Buijsrogge et al. (19); and Iranzo et al. (20), all
the patients who have not a mechano-bullous phenotype form,
have an inflammatory phenotype and (v), for Seta et al. (21),
inflammatory lesions are characteristic of the BP-like form of
EBA but can also be seen in some patients with MM-EBA or IgA
EBA.
The authors of the consensus conference (16) agreed on the
following: (i) BP-like EBA are usually inflammatory forms of
EBA, (ii) MM-EBA may be inflammatory forms of EBA, (iii)
IgA-EBA may be inflammatory forms of EBA, (iv) Brunsting-
Perry-like EBA are usually non-inflammatory forms of EBA, and
(v) Brunsting-Perry-like EBA are not classical/mechano-bullous
forms of EBA.
QUALITY OF LIFE IN EBA AND
ASSOCIATED DISORDERS
In general, EBA has a significant impact on the quality of
life, which is now to be measured by generalized scores and
the “autoimmune bullous disease quality of life” (ABQOL) and
“treatment-based autoimmune bullous disease quality of life”
(TABQOL) scores created specifically for autoimmune bullous
diseases (77, 78).
Many systemic diseases have been reported to be
associated with EBA, such as amyloidosis, thyroiditis, multiple
endocrinopathy syndrome, rheumatoid arthritis, pulmonary
fibrosis, chronic lymphocytic leukemia, thymoma, and diabetes
[review in Gupta et al. (22)]. Most of these reports are, however,
anecdotal. The only unarguable association of EBA with
other diseases is with chronic inflammatory bowel diseases,
in particular Crohn’s disease, which has been reported to be
present in 25% of EBA patients (65, 79). In B-cell lymphomas,
presence of circulating and tissue-bound auto-antibodies to
type VII collagen (COL7) has also been described in association
with a frequency of 6% in 100 EBA cases, but the patients did
not have clinical features suggestive of EBA (80). Furthermore,
EBA associated with systemic lupus erythematosus, but not
fulfilling the criteria of bullous erythematosus systemic lupus,
are described (81, 82).
DIAGNOSIS
If clinically suspected, the minimal diagnostic criteria for EBA
diagnosis are the detection of linear immunoglobulin- or C3-
deposits along the dermal-epidermal junction in a perilesional
skin biopsy with detection of a u-serrated pattern of Ig-binding.
Routine histopathology from a lesional skin (or mucous
membrane) biopsy does not allow to distinguish EBA from other
subepidermal AIBD. It shows: (i) initially, papillary oedema and
vacuolar alteration along the dermo-epidermal junction and at a
later stage, a subepidermal or subepithelial cleavage, (ii) a great
variability in the magnitude and/or quality of the inflammatory
infiltrate, (iii) milia cysts and fibrosis in older lesions (Figure 3).
Definite diagnosis can be performed by either of the following
methods: (i) serration pattern analysis of linear immunoglobulin
deposits in the perilesional skin biopsy, (ii) fluorescent overlay
antigen mapping (FOAM), (iii) immunoelectron microscopy,
and/or (iv) detection of circulating antibodies against COL7.
If possible and needed, more than one of the above may
be used to diagnose or exclude EBA. In addition, serology,
i.e., detection of circulating anti-COL7 antibodies, should be
performed, and, if positive, can serve as a biomarker of disease
severity (83).
Diagnosis of EBA can be made by indirect
immunofluorescence microscopy (IIF) using 1M NaCl-
split skin (SSS) as a substrate (84). Here, binding of antibodies to
the dermal site (floor) of the blister is observed. By immunoblot
analysis, binding to the 290-kDa antigen by the patient IgG is
detected. The newly developed COL7 ELISA has a sensitivity of
45%. Combining SSS and ELISA reaches a sensitivity of 50%.
Thus, half of the patients with EBA are sero-negative (85), and
thus a negative serological finding does not exclude EBA as a
differential diagnosis.
In serological negative cases, direct immunofluorescence
(DIF) on sodium chloride-separated skin biopsy might reveal
the diagnosis. Specifically, the diagnosis can be made using
DIF serration pattern analysis, which shows distinct, EBA-
specific, linear u-serrated immune-depositions at the BMZ
(86). DIF serration pattern analysis by n-vs.-u may consider
require expertise, which can be studied online: “n-vs.-u UMCG”
(https://www.umcg.nl/NL/UMCG/Afdelingen/dermatologie/
Wetenschappelijk_Onderzoek/NversusU/Paginas/default.aspx.
Direct Immunodetection of Perilesional
Skin Biopsies
All pemphigoid diseases are characterized by a linear deposition
of immunoglobulins and/or complement along the epidermal
basement membrane zone (Figure 4A). These antibodies are
directed against various hemidesmosomal proteins: (i) type XVII
collagen (BP180) in BP, MMP, pemphigoid gestationis, lichen
planus pemphigoides, and LAD, (ii) BP230 in BP, (iii) laminin-
332 in anti-laminin-332 pemphigoid, (iv) integrin β4 in ocular
MMP, and (v) p200 in anti-p200 pemphigoid. Moreover, in
EBA and bullous systemic lupus erythematosus (SLE), antibodies
against COL7, present in the sublamina densa, also give rise to a
linear deposition pattern (87).
If in suspected pemphigoid disease, a linear Ig- and/or
C3- deposition is observed, it is important to determine the
targeted autoantigen. In most variants of BP and in EBA,
the deposits consist of IgG and complement. Mixed IgG/IgA
depositions are usually encountered, especially in mucosal
dominant pemphigoid. In some patients, IgA is the only present
Ig-subtype, leading to a diagnosis of LAD or IgA EBA (67, 88, 89).
However, in mucosal dominant pemphigoid with mixed IgA/IgG
depositions, the IgG component may be faint, which sometimes
result in a misdiagnosis of LAD. In very few patients, linear
IgM deposition may be present in addition to IgG and C3. Even
less cases have been described with linear IgM deposition only
(90, 91).
Bullous SLE is characterized by antibodies against COL7 in
patients fulfilling the diagnostic criteria for SLE. In bullous SLE,
in addition to, or superimposed on a linear IgG deposition,
Frontiers in Medicine | www.frontiersin.org 5 January 2019 | Volume 5 | Article 362
Koga et al. EBA Update 2019
FIGURE 3 | Standard histology. (Left) Histological study of lesional skin biopsies in a patient with a classical/mechanobullous form of EBA, subepidermal cleavage
without dermal infiltrate; bottom, milium cyst in the dermis. (Middle) Patient with a BP-like form of EBA, subepidermal cleavage with fibrin in the blister cavity and mild
dermal infiltrate. Bottom, Neutrophils along the dermo-epidermal junction (Right) Patient with a BP-like form of EBA, one intraepidermal bullous lesion and one
subepidermal bullous lesion with dense infiltrate in its cavity prolonged by a cleft in the hair follicle; bottom, a dermal papillary microabcesse of neutrophils.
a biopsy might show a lupus band, which is characterized by
granular deposition of immunoglobulins and complement, in
coincidence with epidermal anti-nuclear antibodies.
In most pemphigoid patients, a linear-serrated pattern can
be discerned in direct IF microscopy of a peri-lesional skin
biopsy. This serration pattern can be divided into an n-serrated
and a u-serrated pattern (Figure 4A). The identification of these
particular patterns allows to differentiate between (i) sublamina
densa binding diseases caused by autoantibodies against COL7,
e.g., EBA and bullous SLE and (ii) blistering diseases with binding
above the lamina densa with antibodies against hemidesmosomal
components, e.g., BP, pemphigoid gestationis, MMP, anti-p200
pemphigoid, and anti-laminin 332 pemphigoid. The u- and n-
serrated patterns form based on the molecular architecture of the
dermal-epidermal junction (DEJ): Specifically, if autoantibodies
against COL7 are present, the immunodeposits are located
between the rootlets of the basal keratinocytes, leading to
the EBA-associated u-serrated pattern (Figure 4A). If, however,
immune-depositions are located above the lamina densa, they
trail the plasma membrane in the basal cell rootlets, resulting
in the n-serrated pattern (Figure 4A). If it is not possible to
determine the serration pattern, which occurs in few cases,
it is recommended wise to cut thinner sections or obtain an
additional peri-lesional skin biopsy.
However, if diagnosis of EBA cannot be established based on
the serration pattern, the level of antibody deposition can be
determined by fluorescent overlay antigen mapping (FOAM),
which is based on the visualization of a targeted antigen relative
to a known topographic marker. For instance, in Figure 4B, red
staining is used for BP180 as a topographic reference, whereas
green staining corresponds to IgA deposits. In the case of
IgA-EBA, separate patterns of IgA deposits (green) and BP180
(red) can be seen with red staining on the dermal side (89).
FOAM can be performed using a standard immunofluorescence
microscope. However, confocal microscopy usually yields better
results.
Direct immunoelectron microscopy provides a more detailed
location of the deposition site, i.e., the lamina densa and/or
sublamina densa at the DEJ (29). This location is distinct from
that in other AIBDs (29, 30, 92).
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FIGURE 4 | Diagnosis of EBA by direct immunofluorescence. (A) All
pemphigoid variants are characterized by linear deposition of immunoglobulins
and/or complement along the epidermal basement membrane zone. Serration
pattern can be separated in an n-serrated pattern (blistering diseases with
binding above the lamina densa with antibodies against hemidesmosomal
components, e.g., BP, pemphigoid gestationis, mucous membrane
pemphigoid, anti-p200 pemphigoid, and anti-laminin 332 pemphigoid, exept
MM-EBA) and a u-serrated pattern (sublamina densa binding diseases caused
by autoantibodies against COL7, e.g., EBA and bullous SLE). (B) In some
cases, it is not possible to determine the serration pattern, especially in
mucosal biopsies. In these cases, the level of the deposition of antibodies can
be determined by fluorescent overlay antigen mapping (FOAM). FOAM is a
technique that is based on the possibility of visualizing a targeted antigen
relative to a topographic marker. For instance, using red staining, it is used for
BP180 as a topographic reference marker, and green staining is used for IgA
deposits. In the case of IgA-EBA, separate patterns of IgA deposits (green)
and BP180 (red) can be observed with red staining on the dermal side.
Indirect Immunofluorescence on Salt-Split
Skin
Diagnosis of EBA can be made by indirect immunofluorescence
(IIF) using 1M NaCl-split skin (SSS) as a substrate. Here,
antibody binding of to the dermal site (floor) of the blister
is observed. By immunoblot analysis binding to the 290-
kDa antigen of patient immunoglobulin is detected (84).
Using SSS as a substrate, IIF shows IgG binding on the
dermal side of the split. IgG binding can therefore be easily
distinguished from BP and, in some cases, MMP, in which




For the serological diagnosis of EBA, three different assays are
available: (i) an enzyme-linked immunosorbent assay (ELISA)
that uses the non-collagenous (NC)1 and NC2 domains of COL7
(15, 93–95), (ii) an ELISA that is based on the NC1 domain
alone (83), and (iii) an indirect IF test employing the NC1
domain (83). If they can be detected, serum levels anti-COL7 IgG
correlate with disease activity (96). However, no correlation has
been detected between the antibody specificity and the clinical
phenotype (97).
THERAPY
First, the treatment of EBA remains challenging because
no randomized control trials have been documented due
to its rare prevalence (98, 99). Similar to other AIBDs,
systemic corticosteroids are widely accepted as a first choice
in the treatment of EBA. Initial doses range from 0.5 to
2.0 mg/kg/day (87). With systemic corticosteroids, steroid-
sparing agents, including colchicine, diaminodiphenyl sulfone
(DDS, dapsone), methotrexate (MTX), azathioprine (AZA),
cyclosporine (CSA), mycophenolate mofetil (MMF), and
cyclophosphamide (CPA), have been reported in treatment
of EBA. Other therapeutic options, including high-dose
intravenous Immunoglobulin (IVIG), rituximab (RTX),
plasmapheresis and immunoadsorption (IA), and extracorporeal
photochemotherapy (ECP) also have been reported (98, 100).
A retrospective analysis included 30 cases from the EBA
cohort study regarding treatment and outcome (18). In this
cohort study, the median time to remission was 9 months, and
complete remission (CR) was observed in 33, 33, and 45% at
1 year, 3 years, and 6 years follow-up, respectively. Relapse
sometimes occurs while receiving therapy, while a rate of relapse
has not been reported in cohort studies.
Very recently, we collected information that included the
treatment of EBA cases who met current diagnostic criteria
published between 1971 and 2016 (101). Among all the reported
treatments, we found IVIG and RTX to be associated with CR.
Based on this retrospective analysis and previous reports in other
autoimmune bullous diseases as a reference, each treatment is
shortly summarized below.
COLCHICINE
In EBA, colchicine is usually used at 1–2 mg/day. Of note,
colchicine monotherapy (2 mg/day) has been reported (20,
102). By some experts, colchicine is considered a first line
EBA treatment, especially for mild cases due to the relatively
minor side effects compared with other therapeutic choices
(103–105). There is currently no controlled study reporting the
efficacy of this treatment, and no experimental data are available.
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Hence, colchicine is a triable treatment for mild cases, and it




Based on expert opinion, DDS is considered a safe and relatively
effective first line treatment (18). Although DDS monotherapy
(100 mg/day) has been reported with CR in single IgA-EBA
cases (67), 25–150 mg/day of DDS is usually used as an
adjuvant therapy with systemic corticosteroids. Adverse effects,
haemolysis, methemoglobinemia, agranulocytosis, peripheral
neuropathy, and psychosis might be observed (106). A rare
adverse effect called “dapsone syndrome” should be considered.
Some experts recommend that this therapy can be effective (105,
107). Similar to BP (108), DDS appears to have a corticosteroid-
sparing effect in EBA.
METHOTREXATE (MTX)
Usually, MTX is used in combination with systemic
corticosteroid with/without other immunosuppressants at
20–25mg weekly. A retrospective review for MTX in the
treatment of pemphigus and pemphigoid has reported the use
of 5–50mg weekly of MTX. Adverse effects, including nausea,
anemia, and infection sometimes led to the discontinuation of
treatment (109). In EBA, no case-series study has focused on the
efficacy of MTX. Based on the efficacy in BP (109), MTX may be
a viable treatment for EBA as a corticosteroid-sparing agent.
AZATHIOPRINE (AZA)
In EBA, AZA was the most frequently used immunosuppressant
as an adjuvant therapy (101). Two types of adverse effects
have been reported; non-dose-related adverse effects, including
pancreatitis, fever, rash, malaise, nausea, diarrhea, and hepatitis,
and dose-related adverse effects, including leucopoenia and some
forms of hepatitis (110). Like MTX, no case-series study has
focused on the efficacy of AZA in EBA. Based on the efficacy in
BP (108), AZA may not be a beneficial treatment for EBA, and
further analysis is needed.
CYCLOSPORINE (CSA)
CSA is mainly used as an adjuvant therapy (101). Renal
dysfunction, hypertension, headache, tremor, paraesthesia,
hypertrichosis, and hyperlipidaemia may be observed as adverse
effects, and most persistent renal dysfunction is related to
prolonged therapy or doses>5 mg/kg/day (111).
MYCOPHENOLATE MOFETIL (MMF)
In our recent, retrospective analysis (101), 1–3 g/day of MMF
was used in combination with systemic corticosteroids. A
randomized clinical trial of methylprednisolone plus-AZA vs. -
MMF therapy in pemphigus showed a slightly lower frequency
of adverse effects, including hypertension, hyperglycaemia, and
infection in the MMF-treated group, although it was not a
significant difference (112). The results from the randomized
control study in pemphigus suggested that 2 g/day offered a better
risk–benefit profile than 3 g/day (113). In a case-series study, EBA
cases were successfully treated with MMF as a steroid-sparing
agent (114). Hence, MMF could be a steroid-sparing agent in
EBA.
CYCLOPHOSPHAMIDE (CPA)
There has been no case-series study focused on the efficacy
of CPA in EBA, and relativity fewer reports have examined
treatment with CPA compared with other immunosuppressants.
Therefore, CPA appears to be a therapeutic option when other




In our recent, retrospective analysis (101), 31 EBA cases were
treated with IVIG, among which 24 cases providing information
on the regimen of IVIG and outcome are summarized in Table 2.
Ahmed et al. reported 10 cases treated with 2 g/kg/cycle (divided
into 3 consecutive days) of IVIG in EBA with severe disease
and non-responsive to conventional therapies (118). After 16–
22 cycles of IVIG therapy, clinical remission was observed from
29 to 123 (mean 53.9) months without any other therapies. The
main adverse effect was headache, which increased the intervals
of each infusion in two cases, although no severe adverse effects
were observed. These two cases are also well summarized in
previous reports of IVIG treatment in EBA. In most cases, 2
g/kg/cycle for 3 days or 400 mg/kg/day for 5 sequential days were
used with clinical improvement. In experimental mouse studies
of EBA and BP, beneficial effects of IVIG have been demonstrated
(128–131). Recently, a randomized double-blind trial of IVIG
was reported in BP showing a lower disease activity score in
the IVIG-treated group compared with placebo (132). Therefore,
IVIG is an effective treatment in severe or intractable cases of
EBA.
RITUXIMAB (RTX)
Rituximab, a humanized anti-CD20 monoclonal antibody, was
used in 10 cases with a protocol of 375 mg/m2 weekly for 4
weeks (in most cases) and was associated with CR in our recent,
retrospective analysis (101), which is summarized in Table 3.
In pemphigus, another regimen, 1,000mg every 2 weeks on
day 0 and day 14 twice and 500mg at 12 and 18 months,
showed good efficacy in an open-label randomized trial (140).
A recent study reported 4 EBA patients treated with 1,000mg of
RTX every 2 weeks twice, similar to the regimen in pemphigus
with PR and CR outcomes in each case and no response in 2
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TABLE 2 | Reports of IVIG treatment in EBA.




Regimen of IVIG Concomitant-started
treatment
Outcome
2013 (115) 37 f BP-like Corticosteroid,
colchicine, DDS
2 g/kg/cycle No response
2013 (116) 20 f BP-like Corticosteroid, DDS 500 mg/kg/day, 4 days colchicine (1 mg/day) CR
2013 (117) 2 m BP-like Corticosteroid 400 mg/kg/day, 4 days DDS (1 mg/kg/day) PR
2011 (118) 55 f BP-like Corticosteroid, AZA 2 g/kg/cycle divided in
3 days
CR
2011 (118) 61 m Mechanobullous Corticosteroid, DDS 2 g/kg/cycle divided in
3 days
CR
2011 (118) 37 m Mechanobullous Corticosteroid, DDS 2 g/kg/cycle divided in
3 days
CR
2011 (118) 55 f Mechanobullous Corticosteroid, DDS 2 g/kg/cycle divided in
3 days
CR
2011 (118) 47 f Mechanobullous Corticosteroid 2 g/kg/cycle divided in
3 days
CR
2011 (118) 50 f Mechanobullous DDS, MMF, MTX 2 g/kg/cycle divided in
3 days
CR
2011 (118) 73 m Mechanobullous Corticosteroid, DDS 2 g/kg/cycle divided in
3 days
CR
2011 (118) 75 f Mechanobullous Corticosteroid, DDS 2 g/kg/cycle divided in
3 days
CR
2011 (118) 59 m BP-like Colchicine, CSA 2 g/kg/cycle divided in
3 days
CR
2011 (118) 62 f BP-like Colchicine, MTX, MFM 2 g/kg/cycle divided in
3 days
CR
2007 (119) 70 m Unknown Corticosteroid, AZA,
DDS, CSA
2 g/kg/cycles PR





400 mg/kg/day, 5 days PR
2007 (121) 58 f Unknown Corticosteroid, AZA,
MMF, CSA
2 g/kg/cycles no response




2006 (122) 54 f Mechanobullous Corticosteroid, AZA,
colchicine,




2002 (123) 43 f Both None 400 mg/kg/day, 5 days CR (PR after
1 cycle)




1998 (46) 59 m Mechanobullous Corticosteroid, DDS,
MTX, CSA, CPA, IA
400 mg/kg/day, 5 days CR
1997 (125) 29 m BP-like Corticosteroid, AZA,
DDS, PE, colchicine,
CSA
40 mg/kg/day, 5 days CR (after 4
cycles)
1995 (126) 55 m BP-like Corticosteroid, AZA,
DDS, colchicine
400 mg/kg/day, 5 days CR (after 9
cycles)
1993 (127) 16 m Both Corticosteroid, CSA 400 mg/kg/day, 4 days
every 2 weeks
CR
BP, bullous pemphigoid; DDS, diaminodiphenyl sulfone; MTX, methotrexate; AZA, azathioprine; CSA, cyclosporine; MMF, mycophenolate mofetil; CPA, cyclophosphamide; IVIG,
high-dose intravenous immunoglobulin; PE, plasma exchange; CR, complete remission; PR, partial remission.
cases (141). In EBA animal models, depletion of B cells at the
induction of experimental disease showed that B cells, in addition
to developing into plasma cells, serve as important antigen-
presenting cells. Specifically, if anti-CD20 treatment was applied
at the time of immunization, development of antigen-specific
CD4+ T cells was significantly hampered in immunization-
induced EBA (142). Hence, RTX seems to be a promising
treatment option for EBA. Further controlled clinical studies are
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TABLE 3 | Reports of RTX in EBA.




Regimen of IRTX Concomitant-started
treatment
Outcome
2013 (133) 71 f Unknown corticosteroid, DDS 375 mg/m2, every
week, 4w, 4 cycles
IA CR (after 18
weeks)













2010 (135) 71 f BP-like Corticosteroid, DDS,
colchicine
375 mg/m2 every
week, 4w, 1 cycle
IA CR (within 16
weeks)














2007 (138) 67 m Mechanobullous Corticosteroid, AZA,





2007 (138) 42 m Mechanobullous Corticosteroid, AZA,

















DDS, diaminodiphenyl sulfone; MTX, methotrexate; AZA, azathioprine; CSA, cyclosporine; MMF, mycophenolate mofetil; CPA, cyclophosphamide; IVIG, high-dose intravenous
immunoglobulin; RTX, rituximab; PE, plasma exchange; IA, immunoadsorption; ECP, extracorporeal photochemotherapy, CR, complete remission; PR, partial remission.




Although plasmapheresis has been used for the treatment of
pemphigus and pemphigoid, including EBA, it makes the shift
to IA because of its advantages compared with plasmapheresis:
(i) selective removal of immunoglobulin from the circulation;
(ii) no requirement for the substitution of plasma components,
such as human albumin or fresh frozen plasma; (iii) two to
three times more processing capacity per treatment session than
plasmapheresis; and (iv) fewer side-effects, such as infections and
allergic reactions (90). Interestingly, there are several reports of
combination therapy with IA and RTX in EBA thatmight provide
an effective treatment protocol in EBA (133, 135, 138). Kolesnik
et al. (133) and Kubisch et al. (135) reported that each patient
was treated with IA for 3 consecutive days followed by IA every
week and 375 mg/m2 of RTX on the day after IA for 4 weeks,
leading CR after 18months and CRwithin 16 weeks, respectively.
Niedermeier et al. (138) reported 2 intractable cases treated
with 2 cycles of IA for 4 consecutive days at 4-week intervals
followed by RTX (375 mg/m2, every week for 4w), leading to
PR. Interestingly, antigen-specific immunoadsorption, i.e., where
only autoantibodies specific for the respective autoantigen are




ECP has been reported in the treatment of Sezary syndrome,
mycosis fungoides, and autoimmune bullous diseases (145).
There are several reports of the use of ECP in refractory EBA
with outcomes of CR and PR in 3 cases, respectively, and no
response in 1 case (61, 100, 146, 147). The mode of action of
ECP in the treatment of EBA is still unknown, although one
report has shown a decrease in circulating antibody detected
by immunofluorescence and an increase in suction blister time
(100). Despite the low number of published EBA patients, due
to the reported success rates, ECP should be considered a
therapeutic option in patients with refractory EBA.
OTHERS
Daclizumab, a humanized monoclonal antibody against the a-
subunit of the high-affinity interleukin-2 receptor also known
as the Tac antigen or CD25, was reported in the treatment
of EBA (148), in which only one of 3 cases showed clinical
improvement. Sulfasalazine was used in a patient with EBA
associated with Crohn’s disease, resulting in no improvement of
the skin lesion (149). The usefulness of doxycycline has been
reported in BP (150). Doxycycline and another tetracycline,
minocycline, were found in the literature on EBA cases,
although its usefulness remains unclear in EBA treatment (151–
153).
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PROGNOSIS
EBA is a chronic disease characterized by exacerbations and
remissions over the course of months to years. Although data on
the prognostic factors in EBA are lacking in the literature, the
experts admit that the prognosis of EBA depends on its severity
at the time of diagnosis and propose treatment accordingly.
Analogous to BP (154, 155) and MMP (35), an EBA is
considered severe if the patient has 10 or more cutaneous
bullous lesions and/or 3 or more instances of mucosal sites
and/or conjunctival, laryngo-tracheal or esophageal involvement.
Otherwise, the EBA is classified as moderate or minimal. The
MMP-DAI (disease activity index) score (156) can be used to
quantify the extent of the disease, but the cut-offs between the
severe, moderate, and minimal forms of EBA have not been
established to date.
The goal of the treatment is to obtain control of the disease
followed by CR, i.e., the absence of active lesions (erythema,
urticaria, bullous lesions, and erosions) without worsening of the
cicatricial lesions, which are irreversible.
A CR off treatment of EBA is not possible since a long-term
maintenance treatment is recommended. CR under minimal
treatment may occur after months to years in mild or moderate
forms (unpublished data), but minimal skin fragility without
bullous lesions can persist for several months to years. The
milium cysts may eventually disappear.
The prognosis has been reserved in severe forms, as evidenced
by the publication of numerous case reports in therapeutic
failure. Indeed, in some patients, the disease may progress
quickly with periods of severe exacerbation and rapid scarring.
The cicatricial lesions (synechiae, stenosis, joint contractures)
may engage the functional prognosis and be life-threatening.
In a retrospective study of 30 patients with EBA, all of whom
were initially treated with a combination of methylprednisolone,
dapsone, and colchicine (six who did not respond were
subsequently treated with other immunosuppressants), 8 of 24
patients (33 percent) achieved complete remission and 5 of
24 (21 percent) achieved partial remission within 1 year (18).
The prognosis of these severe forms could improve because
of recent publications demonstrating the therapeutic success
of intravenous immunoglobulins and rituximab (see above).
The overall prognosis and response to treatment may be more
favorable in children than in adults (157, 158).
Taken together, these findings underline the need for an early
diagnosis, multidisciplinary care by experienced practitioner and
prompt implementation of appropriate treatment to improve the
prognosis of EBA.
PATHOGENESIS
COL7 as the Autoantigen in EBA
Nearly a century after the first description of EBA, the carboxyl
terminus of COL7 was identified as the autoantigen in EBA.
Since that time, it has been shown that most patients develop
autoantibodies that bind to epitopes located within the NC1
domain of COL7 (159–162), whereas antibody reactivity to either
the collagenous domain (163) or the NC2 domain (164) is
detected in a very small minority of patients. No correlation
was detected between antibody specificity and clinical phenotype
(159). In a recent multicentre study with 95 EBA patients,
NC1/NC2 ELISA showed a higher sensitivity (97.9%) than NC1
ELISA (89.5%), supporting a considerable number of patients
with antibodies against NC2 (95).
Interestingly, the humoral autoimmune response toward
COL7 encompasses almost all IgG subclasses. Most commonly,
COL7 autoantibodies are IgG, but in ∼10% of EBA patients,
IgA autoantibodies against COL7 are detected. Few cases of IgE-
and IgM-COL7-reactive immunoglobulins have been described
(101). The nature and/or cause of this broad immunoglobulin
isotype reactivity against COL7 is, however, unknown.
GENETIC AND ENVIRONMENTAL
FACTORS CONTRIBUTE TO TOLERANCE
LOSS IN EBA
As with most autoimmune diseases, the exact cause of the
disease is unknown. With regard to EBA, the data indicate
a certain genetic predisposition as well as a contribution of
environmental factors to EBA pathogenesis. Due to the small
number of EBA cases, it is difficult to study the influence of
certain environmental factors or infections. EBA susceptibility is
associated with genes in and outside the major histocompatibility
complex (MHC) locus. Specifically, an association with the MHC
locus (HLA-DR2) has been documented in humans in two
independent studies (10, 11). The association with the MHC
locus is also supported by animal studies, where an association of
susceptibility to immunization-induced EBA is linked to the H2s
locus (165). Evidence for the involvement of genes outside the
MHC locus arises from one case of coincident EBA inmembers of
a family provided further support for the genetic control of EBA
(166). The contribution of genes outside the MHC locus is again
underscored by corresponding observations in experimental EBA
(165, 167, 168). First, when C57Bl6/J mice are immunized with
COL7, they develop autoantibodies but no clinical disease. When
mice on the same genetic background lack expression of the
inhibitory Fc gamma receptor (FcγR) IIB, they also develop
clinically overt blistering (165, 168). Similarly, mice carrying
the EBA-associated H2s allele develop severe clinical disease
when on the B6 genetic background but only moderate disease
when on the C57BL/10 background (165, 169). To pinpoint
the mutations associated with EBA susceptibility, mice of an
advanced, autoimmune-prone intercross line were immunized
with COL7. Herein, one third of the mice developed clinical
disease, while the remaining mice remained phenotypically
healthy (170, 171) Classical quantitative trait loci mapping
identified several genes outside the MHC that were associated
with either the onset or severity of clinical disease (170).
However, the number of genes is still too large to pinpoint the
association with clinical disease to single genes, yet in a nutshell,
it provides evidence for a genetic basis of EBA susceptibility.
In addition to genetic factors, animal models of EBA clearly
indicated an influence of resident microbial communities in
disease pathogenesis (172, 173) (Figure 5). By the use of
outbred mice in immunization-induced EBA, it could be shown
that Firmicutes were the most abundant (54%), followed by
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Proteobacteria (21%), Actinobacteria (12%), and Bacteroidetes
(6%), which is similar to previous studies in the skin. At the
genus level, Staphylococcus (36%), Corynebacterium (9%), and
Ralstonia (8%) were most abundant (172). Ellebrecht et al. used
the same model to show skin community changes before and
after immunization. Among SJL/J mice that were immunized
with COL7, only 80% of the mice developed disease, whereas
the others remained healthy. Interestingly, the specific antibody
concentrations and binding of antibodies to the DEJ were
unaffected. By contrast, immunized mice that did not develop
clinical phenotypes showed a greater alpha diversity, compared
to mice that developed EBA symptoms after immunization (173).
THE AFFERENT PHASE: CD4T
CELL-DEPENDENT PRODUCTION OF
AUTO-ANTIBODIES AGAINST COL7
EBA is characterized and causes autoantibodies directed
against COL7. Unfortunately, little human data are available
for this relevant and complex phase of pathogenesis, which
includes the interaction of various immune cells, such as
antigen-presenting cells, autoreactive B cells, T cells and
neutrophils, and subsequently leads to antibody production.
Regarding human data, COL7-specific T cells (isolated
from the blood) can be detected EBA patients (174, 175),
but most data concerning the interaction of these cell in
the afferent phase has been derived from animal models
(167).
In the immunization-induced EBA model, T-cell-deficient
mice do not develop COL7-specific antibodies and, consequently,
clinical disease development, indicating that autoantibody
production in this model is T cell-dependent. Furthermore,
disease susceptibility could be restored in T cell-deficient SJL/J
mice by T cells transfer from COL7-immunized wild-type mice
(176). To delineate T-cell subsets involved in the generation of
anti-COL7 antibodies in this model of immunization-induced
EBA, CD4+ and CD8+T cells were depleted for 2 weeks, starting
at immunization. Depletion of CD4+ T cells led to a delay of
both autoantibody production and the clinical disease onset. By
contrast, CD8+ T cells depletion at the same time period did not
impact production of COL7-specific autoantibodies or clinical
disease (142). Therefore, in experimental EBA, CD4+ T are
required for induction of autoantibody production. Since only
few and specific inbred mouse strains developed clinically overt
disease after COL7 immunization, the autoantibody response
of clinically healthy vs. diseased mice after immunization was
contrasted. Here, complement-fixing antibodies were linked to
clinical EBAmanifestation (169). Furthermore, by determination
of the IgG isotype of the autoantibodies, a Th1 polarization of
the immune response was noted. In addition, an increase in
the Interferon (IFN)-γ/Interleukin (IL)-4 ratio in the draining
lymph nodes of EBA-susceptible mice compared with EBA-
resistant strains was observed (169). Regarding the involvement
of neutrophils in autoantibody production, GM-CSF-deficient
mice generated less COL7-specific autoantibodies, which was
paralleled by reduced neutrophil numbers in peripheral lymph
nodes, draining the immunized site. The same effect was
observed in neutrophil-depleted wild-type mice (177).
To further address which antigen-presenting cells are required
the formation of antigen-specific CD4+ T cells, B cells were
depleted in mice and subsequently immunized with COL7. In the
absence of B cells, the antigen-specific CD4+ T-cell response was
completely abolished. Furthermore, depletion of dendritic cells
and macrophages had similar effects. Hence, the development
of COL7-specific CD4+ T cells requires the presence of APC—
specifically B cells, dendritic cells, and macrophages (142)
(Figure 5). More interestingly, the absence of Treg cells in scurfy
mice cells led to blistering via the formation of pathogenic
autoantibodies, demonstrating a critical involvement of these cell
types in the afferent phase of EBA (178, 179).
In contrast to T cells, autoreactive B cells are almost
exclusively found in the peripheral lymph nodes in the
immunization-induced EBAmouse model (180, 181), which may
be due to missing expression of homing-associated CXCR3 and
CXCR4 chemokine receptors. In immunization-induced EBA,
COL7-specific plasma cells have a half-life of ∼7 weeks. This
resembles an intermediate between short- and long-living plasma
cells (180). A similar intermediate plasma cell type is most likely
also present in patients because autoantibody titers in patients
with autoimmune bullous diseases slowly decline over a period
of 8–12 weeks after B cell-depleting rituximab treatment (182).
An important molecular requirement for autoantibody
production in experimental EBA is heat-shock protein 90
(Hsp90). Specifically, pharmacological HSP90 inhibition
suppressed autoantibody production in immunization-induced
EBA. In the same model, HSP90 blockade impaired the
onset of clinical disease manifestation when injected prior
to immunization with COL7. Furthermore, clinical disease
progression was ameliorated when the compounds were applied
in therapeutic experimental settings. Interestingly, B cell
development was unaffected by the HSP90 inhibition, while
T-cell proliferation was impaired. Overall, this identified T cells
as targets of HSP90 inhibition in experimental EBA (174).
CIRCULATION AND PATHOGENICITY OF
AUTOANTIBODIES AGAINST COL7
Targeting the Half-Life of Anti-COL7
Autoantibodies
After (auto)-antibodies are present in the circulation, their half-
life is controlled by the neonatal Fc receptor (FcRn). FcRn
is constructed as a heterodimer, consisting of an alpha-chain
and a beta-2-microglobulin light chain (183). Among other
functions, FcRn protects IgG from catabolism (184). Inhibition
of the FcRn leads to the enhanced clearance of IgG, including
autoantibodies. In antibody transfer-induced animal models of
EBA (167), disease induction in mice is completely blocked (128,
185). However, this protection can be overridden by the transfer
of large amounts of antibodies (185). Similarly, treatment of
experimental EBA or other pemphigoid diseases with high doses
of IgG (IVIG), which by saturation also inhibits the FcRn, reduces
circulating autoantibody titers and leads to disease improvement
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FIGURE 5 | Pathogenesis of EBA. (1) Genetic factors and the skin microbiome promote a tolerance loss. (2) This phenomenon is mediated by the interaction of APCs
with autoreactive B and T cells, leading to clonal expansion and differentiation into plasma cells. Autoantibodies against COL7 are released into the blood circulation
and effector organs. (3) During inflammation, galactosylation of antibodies may differ. High galactosylation of IgG is crucial for these anti-inflammatory properties,
(Continued)
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FIGURE 5 | whereas low galactosylation is pro-inflammatory. (4) Binding of autoantibodies to DEJ in the skin induces complement deposition, pro-inflammatory
cytokine and mediator release and subsequently leukocyte extravasation. (5) Immune complexes bind in a Fc-dependent manner to neutrophils and induce a signaling
cascade leading to activation, including the (6) release of ROS and matrix metalloproteases. In addition to neutrophils, other cell types are involved in split formation,
as shown for monocytes/macrophages, NKT and γδ T cells. By contrast, Treg cells have an inhibitory effect on EBA progression. (7) Resolution of
autoantibody-induced tissue injury. Treg, regulatory T cell; NKT, natural killer cell; C, complement; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL,
interleukin; LTB4, leukotriene B4; PDE4, phosphodiesterase 4; ROS, reactive oxygen species; NADPH, nicotinamide adenine dinucleotide phosphate; MMPs, matrix
metalloproteinases; APC, antigen-presenting cell; CD, cluster of differentiation; SYK, spleen tyrosine kinase; Lyn, tyrosine-Protein Kinase Lyn; HSP, heat shock protein;
AKT, protein kinase B; NCF1, neutrophil cytosolic factor 1; ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; HCK,
tyrosine-protein kinase HCK; FGR, tyrosine-protein kinase FGR; RORα, retinoid-related orphan receptor-alpha; BLT1, leukotriene B4 receptor 1; LTB4, leukotriene B4.
(128, 129, 186, 187), although FcRn inhibition is most likely not
the only mode of action of IVIG in EBA (131, 188, 189).
Interestingly, two clinical trials are currently being conducted
to evaluate the safety and efficacy of FcRn inhibitory treatments
in patients with other autoimmune skin blistering diseases
(NCT03334058) (190). Hence, this may become a treatment
option for EBA patients in the not too distant future (167).
Targeting the Pathogenicity of Anti-COL7
Autoantibodies
In addition to its half-life, the pathogenicity of an antibody
can also affect disease progression. In general, IgG antibodies
have one conserved N-glycosylation site in each of their
constant heavy chain regions. These Fc glycans have a major
impact on their structure as well as their effector functions.
Non-galactosylated (agalactosylated; G0) IgG antibodies
have long been thought to have pro-inflammatory effector
functions in autoimmune patients with rheumatoid arthritis.
In contrast, sialylated IgGs mediate anti-inflammatory effects.
Recent evidence also suggests that pro-inflammatory immune
responses, including autoimmune reactions, mainly induce
antigen-specific G0 IgGs, whereas tolerance leads to the
generation of immunosuppressive, galactosylated, and sialylated
IgGs. Under normal conditions, differentially glycosylated
IgGs clearly mediate their pro- or anti-inflammatory effector
functions as immune complexes in an antigen-specific manner
(191) (Figure 5). In agreement with these findings, the use of
EndoS, an endoglycosidase derived from Streptococcus pyogenes
that selectively hydrolyses the N-linked glycan of native IgG,
impaired split formation at the DEJ in skin cryosections. In EBA
mouse models, EndoS abrogated clinical disease induction in
mice (192, 193). This observation raises the possibility that the
glycosylation status of IgG can also affect the onset, severity and
progression of disease.
THE EFFERENT PHASE OF EBA:
ATTRACTION AND ACTIVATION OF
LEUKOCYTES LEADS TO BLISTER
FORMATION
Based on the current understanding of EBA pathogenesis
(Figure 5), the effector phase of EBA, i.e., autoantibody-
induced inflammation and blistering, can be divided into (i)
autoantibody binding to COL7, (ii) complement activation and
the formation of a pro-inflammatory milieu, (iii) leukocyte
extravasation, (iv) activation by Fcγ receptors, and (v) tissue
damage. Mechanisms leading to non-inflammatory blistering
in EBA are, in contrast, poorly understood. With the increased
understanding of pathomechanisms of epitope-dependent
pathogenicity-associated (194), non-inflammatory BP, new
insights into mechanobullous EBA can be expected. However,
due to a lack of data on non-inflammatory mechanisms of
blistering in EBA, the following text relates to inflammatory
EBA.
Autoantibody-induced tissue injury in EBA is initiated by
(i) the deposition of autoantibodies at the DEJ. Apart from
the skin anti-COL7 antibodies bind to the esophagus, stomach,
small intestine, and colon because of the autoantigen expression
at these sites (195, 196). Yet, not all isotypes of anti-COL7
have the potential to induce dermal-epidermal separation: Ex
vivo, only human IgG1 and IgG3, but not IgG2 and IgG4,
are capable to cause blistering (197). Furthermore, immune
complexes containing IgA1 or IgA2 COL7 autoantibodies
activate neutrophils and also induce subepidermal blistering
when in cryosections of human skin. Of note, and in
contrast to IgG1 autoantibodies, neither IgA1 nor IgA2 leads
to complement deposition at the dermal-epidermal junction.
Because complement activation has traditionally been thought a
prerequisite for blister induction, this may be compensated by so
far unknown soluble factors and/or by a stronger activation of
neutrophil granulocytes when engaging IgA immune complexes
(198).
Thereafter, (ii) a pro-inflammatory milieu is generated in
the skin, which includes activation of the complement system
(199). The complement system consists of circulating proteins
that, upon activation, initiate a highly controlled cascade that is
an integral part of the innate humoral immune response (200).
C5-deficient mice (168) are either completely or (168) partially
(201) protected from induction of experimental EBA by antibody
transfer.
Dissecting the specific role of each complement activation
pathway (classical, lectin, and alternative pathway) showed
the following: MBL deficient mice showed a similar EBA
phenotype to the wild-type controls. C1q-deficient mice showed
weak and partial protection, while factor-B-deficient mice
showed clinically relevant protection from EBA induction by
antibody transfer (199). This identified the alternative pathway
of the complement system as a main driver of skin blistering
and inflammation in antibody transfer-induced EBA (202).
Downstream of C5, C5ar1-deficient mice are significantly
protected from experimental EBA, whereas C6-deficient
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mice developed widespread blistering disease, excluding the
membrane attack complex as a pharmacological target for EBA.
In line, pharmacological blockade of C5, factor B, or C5aR1
led to a significant improvement of the blistering phenotype in
antibody transfer-induced EBA (202, 203).
In addition to the complement system, the lipid mediator
leukotriene B4 (LTB4) is a potent granulocyte chemoattractant
(204, 205) and activator (206) and is abundant in the blister fluids
of bullous pemphigoid patients, but its pathogenic significance
for pemphigoid diseases had been unknown until recently.
LTB4 is biosynthesized from arachidonic acid through sequential
enzymatic conversion by 5-lipoxygenase and LTA4-hydrolase.
The 5-lipoxygenase is most abundant in neutrophils, and it
is activated upon cell stimulation by, for example, immune
complexes or the complement fragment C5a (207).Mice deficient
in 5-lipoxygenase, a key enzyme in LTB4 biosynthesis, or BLT1-
deficient mice are completely resistant to the induction of
experimental EBA by antibody transfer (208). In addition to
complement and lipid mediators, several cytokines have been
identified to modulate the effector phase of EBA. Cytokines
that are differentially regulated in experimental EBA (209)
or cytokines associated with those functional data (210) are
summarized in Table 4 (171, 224).
The pro-inflammatory milieu induces the (iii) attraction
of different leukocyte populations (Table 5). Unfortunately,
the composition of these cells has not been investigated thus
far in EBA patients, but it is known from BP patients that
the infiltrate includes cells such as lymphocytes, histiocytes,
eosinophils, neutrophils, and mast cells (228, 229). Subsequent
mechanistic studies using the antibody transfer-induced model
have uncovered neutrophils as the major culprits responsible
for blister formation (208). The recruitment of neutrophils into
the skin is mediated by CD18- and ICAM-1 (216, 230–232).
In addition, CD18 crucially regulates neutrophil adhesion as an
indispensable step leading to tissue damage (233).
Concerning the functional role of T cells, it was recently
demonstrated that T cells can enhance neutrophil recruitment
into the site of inflammation by modulating the expression of
the cell surface integrin CD18 on neutrophils. Interestingly, this
effect was neither mediated by CD4 nor CD8 cells, but rather
γδT and NKT cells (225). Interestingly, blockade of Treg led to
a dramatic worsening of the clinical disease manifestation in
antibody transfer-induced EBA (224).
In addition to granulocytes and lymphocytes,
macrophages/monocytes may be involved in the blister
formation in EBA. However, the blockade of these cells is
technically difficult and does not effectively impair disease
progression (142). Nevertheless, more studies are needed
because macrophages/monocytes are able to produce high
amounts of reactive oxygen species (ROS) after immune
complex stimulation and induce ex vivo split formation in
human skin sections (214). Furthermore, the application of high
concentrations of anti-COL7 IgG has been shown to induce mast
cell activation, but mast cell deficient mice develop experimental
EBA just like wild type animals, indicating that mast cells do
not contribute to the immune-mediated tissue injury (234–236).
Concerning the role of additional cell types in inflammation,
a possible role of plasma cells (227) has been discussed, but
further studies are needed to unravel the cellular orchestration
responsible for the lesional sites.
After extravasation from the blood into the skin, (iv) myeloid
effector cells bind to the skin-bound immune complexes
in a FcγR-dependent fashion (Table 6). In EBA the full IgG
molecule of the autoantibodies, but not their corresponding
F(ab)2 fragments, are pathogenic. Specifically, only the full anti-
COL7 IgG elicits dermal-epidermal separation when, together
with PMN, incubated on cryosections of human skin (248).
Likewise, and unlike the full IgG, F(ab
′
)2 fragments of anti-COL7
IgG do not induce clinical EBA manifestation when injected
into mice (168). The central role of these Fc-FcγR interactions
for mediating skin inflammation and subepidermal blistering
in experimental EBA is further supported by the complete
protection of mice toward EBA induction when injected with
chicken anti-mouse COL7 IgY, which is known not bind to
murine complement and Fc receptors (249). In addition, the
therapeutic effects observed when blocking these interactions,
i.e., using soluble CD32/SM101 (231), highlights the key role
of Fc-FcγR interactions in EBA pathogenesis. Furthermore,
IgG glycosylation has been shown to have preventive and
therapeutic effects in mouse models of chronic inflammatory
diseases, including EBA (191). Further studies eluted on the
differential contribution of the different FcγR (250). In mice,
three different activating FcγR and one inhibitory FcγR are
described: FcγRI, FcγRIII, and FcγRIV are activating FcγR, all
with specific binding avidities toward IgG. The FcγRIIB is the
only inhibitory FcγR (250). Of note, an increased expression
of FcγRIV has been demonstrated in the skin of mice with
experimental EBA (181). Subsequent functional studies identified
the FcγRIV as the key mediator of tissue injury in EBA. By
contrast, blockade of FcγRI, FcγRIII, or both receptors in
combination had no effect on the induction of experimental
EBA by antibody transfer. In FcγRIIB deficient mice enhanced
blistering was observed in antibody transfer-induced EBA, as
well as BP (181, 251), indicating a protective role of this
FcRγ in experimental EBA. In human ex vivo models of
BP, FcγRIIA, and FcγRIIIB contributed to the autoantibody-
induced tissue damage (252). Once the neutrophils are bound
to the immune complexes, a multifaceted signaling cascade
is initiated (Table 6). This involves activation of the retinoid-
related orphan receptor (ROR)α (230), heat shock protein
(HSP)90 (241), phosphodiesterase 4 (240), phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K) β and δ (238, 239), p38, AKT,
ERK1/2 (244), the spleen tyrosine kinase SYK (171, 245), and
src kinases (247), as well as CARD9 (246)—which have been
reviewed in detail elsewhere (253). The exact temporal and
spatial order of these signaling events is currently unknown.
Ultimately, the signaling cascade leads to the activation of
myeloid effector cells, specifically release of ROS and proteases,
both of which are required for subepidermal blistering in EBA
(216, 225).
Recently the contribution of cytokines in EBA pathogenesis
has been eluted both on the morphological, as well as the
functional level (254). Because biologics targeting cytokines are
already in clinical use—although, with few exceptions such
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TABLE 4 | Mediators of the EBA effector phase.
Target Function References
C5 C5-deficient mice are partially or completely protected from EBA inducing by antibody transfer (201, 211)
C1q/factor B Respective knock-out mice are partially protected from EBA inducing by antibody transfer (203)
IgG glycosylation Enzymatic removal of terminal IgG N-glycosylation renders anti-COL7 antibodies non-pathogenic in
antibody transfer-induced EBA
(192, 193)
Galactosylated IgG Immune complexes with highly galactosylated immune complexes inhibit pro-inflammatory signaling of
the C5aR1 through dectin-1 and Fc gamma receptor IIB, resulting in a protection from antibody
transfer-induced EBA
(202)
IL-6 In antibody transfer-induced EBA, IL-6 has anti-inflammatory effects, through up-regulation of IL-1ra (209)
CXCR-1/2 Blockade of the CXCR-1/2 ligands impairs induction of EBA by antibody transfer and slows disease
progression when applied in therapeutic settings in immunization-induced EBA
(212)
GM-CSF Blockade of GM-CSF impairs induction of EBA by antibody transfer and slows disease progression
when applied in therapeutic settings in immunization-induced EBA
(177)
IL-1/IL-1ra Both anti-IL1β or IL-1ra (anakinra) treatment impair the induction of EBA by antibody transfer. Additionally,
anakinra halts disease progression when applied therapeutically in immunization-induced EBA
(213)
TNFa Blockade of TNF impairs induction of EBA by antibody transfer and halts disease progression when
applied in therapeutic settings in immunization-induced EBA
(214)
LTB4 Blockade of either LTB4 biosynthesis or its’ receptor completely protects mice from EBA induction by
antibody transfer
(208)
IL-17A/E IL17R-deficient mice are partially protected from EBA inducing by antibody transfer (215)
NADPH oxidase Neutrophil cytosolic factor 1-deficient mice, lacking functional NADPH oxidase, -deficient mice are
completely protected from EBA inducing by antibody transfer
(216)
Elastase Elastase is required for the induction of subepidermal blisters ex vivo (217)
Flii Blockade of Flii protects mice from EBA induction by antibody transfer (218–220)
MIP1α Increased expression, but no effect on clinical phenotype (221)
S100 Increased expression, but no effect on clinical phenotype (222)
Trem1 Increased expression, but no effect on clinical phenotype (223)
C, complement factor; IgG, immunoglobulin G; IL, interleukin; COL7, type VII collagen; CXCR, CXC-chemokin receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor;
TNF, tumor necrosis factor; LTB, leukotriene; NADPH, nicotinamide adenine dinucleotide phosphate; Flii, flightless I; MIP1α, macrophage inflammatory protein1α; Trem1, Triggering
receptor expressed on myeloid cells-1.
TABLE 5 | Cell lineage in the effector phase.
Cell type Function References
Neutrophils Neutrophil depletion partially protects from EBA induction by antibody transfer (208, 216)
NKT/γδ T cells Depletion of NK or γδ T cells partially protects from EBA induction by antibody transfer (225)
Tregs Depletion of Tregs worsens the clinical disease manifestation in antibody transfer-induced EBA (224)
Keratinocytes Upon binding of COL7 antibodies, pro-inflammatory mediators are released from keratinocytes (209, 226)
IL-10+ B lineage cells IL-10, derived from IL-10+ B cells impairs neutrophil functions and impairs clinical disease manifestation
in immunization-induced EBA
(227)
Monocytes/macrophages Monocytes/macrophages induce subpeidermal splits ex vivo, and depletion of all myeloid cells
completely protects from EBA induction by passive antibody transfer, while selective depletion of
neutrophils confers partial protection
(214, 216)
NKT, natural killer T cells; Tregs, regulatory T cells; IL, interleukin.
as rituximab and omalizumab, for other indications (255)—
we here highlight their contribution for EBA pathogenesis.
Several cytokines have been shown to contribute to blister
formation in experimental EBA (Table 4). IL-6 acts as a pro-
inflammatory cytokine in various autoimmune diseases (256,
257). Hence, IL-6 has emerged as a potential target for the
treatment of autoimmune diseases, and IL-6-targeting therapies
are licensed for rheumatoid arthritis and juvenile idiopathic
arthritis (256). In EBA patients and in experimental EBAmodels,
serum IL-6 levels are elevated. Unexpectedly, mice lacking IL-6
expression show an increased clinical phenotype in experimental
EBA compared with controls. Furthermore, treatment with
recombinant IL-6 leads to a dose-dependent reduction of clinical
disease manifestation in EBA induced by antibody transfer. Thus,
in experimental EBA, IL-6 has a profound anti-inflammatory
activity (209). At the molecular level, the protective effect of IL-6
is mediated by the IL-6-dependent release of IL-1ra (213). In line,
IL-1R–deficient mice or wild-type mice treated with either the
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TABLE 6 | Receptors and signaling in the efferent phase of EBA.
Target Function References
FcγRs Activating FcγR promote skin inflammation in experimental EBA, while the inhibitory FcγRIIB confers
protection from induction of EBA by antibody transfer
(181)
FcRn The FcRn controls the half-live of IgG. This FcRn-deficient mice are partially protected from EBA
induction by antibody transfer
(185)
CD18 CD18-deficient mice are completely protected from EBA induced by antibody transfer (216)
CD11b CD11b-deficient develop a more severe clinical phenotype in antibody transfer-induced EBA. (237)
C5aR1 C5aR1-deficient mice are almost completely protected from EBA induced by antibody transfer (202, 203)
CXCR1/2 Pharmacological CXCR1/2 inhibition prevents disease progression in immunization-induced EBA (212)
BLT1 BLT41-deficient mice are almost completely protected from EBA induced by antibody transfer (208)
PI3Kß PI3Kβ-deficient mice are partially protected from EBA induction by antibody transfer, through inhibition of
neutrophil activation
(238)
PI3Kδ Pharmacological inhibition of PI3Kδ impairs induction of EBA by antibody transfer and has therapeutic
effects in immunization-induced EBA
(239)
Phosphodiesterase 4 Pharmacological inhibition of PDE4 impairs induction of EBA by antibody transfer and has therapeutic
effects in immunization-induced EBA
(240)
RORα RORα-deficient mice are completely protected from EBA induced by antibody transfer (230)
HSP90 HSP90 is involved in both loss of tolerance to COL7, as well as to antibody-induced tissue damage in
experimental EBA
(241, 242)
JAK2 Pharmacological inhibition of JAK2 impairs induction of EBA by antibody transfer and has therapeutic
effects in immunization-induced EBA
(243)
AKT, ERK, p38 Pharmacological inhibition of these targets impairs induction of EBA by antibody transfer (ERK, p38) or
impairs subepidermal splitting ex vivo (all)
(244)
SYK Pharmacological inhibition of SYK or SYK-deficient mice are completely protected from EBA induction
by antibody transfer
(171, 245)
CARD9 CARD9-deficient mice are partially protected from EBA induction by antibody transfer (246)
Src kinases Hck, Fgr and Lyn-tripple-deficient mice are partially protected from EBA induction by antibody transfer (247)
TREM1 See Table 5 (223)
Caspase 1 Caspase-1/11-deficient mice develop antibody transfer-induced EBA similarity to wild type littermate
controls
(213)
FcγR, Fc gamma receptor; FcRn, neonatal Fc receptor; BLT, leukotriene B4 receptor; CXCR, CXC-chemokin receptor; PI3K, Phosphatidylinositol-4,5-Bisphosphate 3-kinase; RORα,
retinoid-related orphan receptor-alpha; HSP90, heat-shock protein 90; JAK2, Janus kinase 2; AKT, protein kinase B; ERK, extracellular signal-regulated kinase; SYK, spleen tyrosine
kinase; CARD9, Caspase recruitment domain-containing protein 9; SRC, tyrosine-protein kinase SRC; HCK, tyrosine-protein kinase HCK; LYN, tyrosine-protein kinase LYN; TREM1,
Triggering receptor expressed on myeloid cells-1.
IL-1R antagonist Anakinra or a IL-1β function blocking antibody
are also partially protected from the EBA-inducing effects
of anti-COL7 IgG. Mechanistically, IL-1β increases ICAM-1
expression on endothelial cells, suggesting that IL-1β supports
recruitment of inflammatory cells into the skin. Interestingly,
these effects of IL-1 were independent of caspase-1 because
of caspase-1/11–deficient mice showed a similar phenotype
to wild type control animals when injected with anti-COL7
IgG (213).
Additionally, the evaluation of cytokines affecting neutrophil
functions, such as IL-8 (CXCL1 and CXCL2 in the mouse) and
GM-CSF in experimental EBA, showed an increased expression.
To evaluate if the increased expression is of functional
relevance these cytokines were inhibited by either antibodies
of mice lacking expression of the respective cytokine(s).
Treatment with allosteric CXCR1 and 2 inhibitors (DF2156A)
impaired the induction of skin blistering in antibody transfer-
induced EBA.
In a therapeutic setting, the administration of DF2156A
improves the clinical manifestation of EBA after disease onset
in immunization-induced EBA (212). For the evaluation of
GM-CSF, anti-COL7 IgG was injected into GM-CSF-deficient
mice or wild type mice treated with a function-blocking GM-CSF
antibody. The induction of experimental EBA was impaired
if the function of GM-CSF was blocked in comparison to
appropriate controls. In vitro studies have demonstrated the
requirement of GM-CSF for neutrophil recruitment from
bone marrow into the blood and from the blood into the
skin. Furthermore, GM-CSF preactivates neutrophils, leading
to an enhancement of immune complex-induced neutrophil
activation. In a therapeutic setting, the blockade of GM-CSF
in mice with already established immunization-induced EBA
has demonstrated beneficial therapeutic effects (177, 213). In
addition to these cytokines, increased expression of TNF has
been observed in experimental EBA, and prophylactic blockade
of TNF and therapeutic use of etanercept in the immunization-
induced EBA model impair the induction and progression of
experimental EBA (214). By contrast, increased expression of
CCL3/MIP1α is a mandatory cytokine for disease development
(221).
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THE RESOLUTION PHASE OF EBA
For most autoimmune bullous diseases, the location of blisters
differs over time, indicating a frequent, but unfortunately overall
insufficient, healing process in the skin (Figure 5). Flightless I
(Flii), an actin remodeling protein, has been shown to modulate
the resolution of skin blistering in experimental models of EBA.
In vivo, the induction of EBA leads to increased cutaneous Flii
expression, resulting in impaired Claudin-1 and Claudin-4 tight
junction protein expression, as well as a delay in the recovery
from blistering (218, 258). Overexpression of Flii produces severe
blistering post-induction of EBA, while decreased Flii reduces
blister severity, elevates integrin expression, and improves
COL7 production. In addition, topically applied Flii neutralizing
antibodies improve the healing of blistered skin in murine EBA
(218–220, 259).
An interesting experiment could show a protective effect
of IL-10-positive plasma cells toward the neutrophil-dependent
inflammation in EBA. After the start of skin inflammation,
plasmacytosis is induced by injection of goat anti-mouse
IgD serum and provides protection from skin inflammation
and neutrophil infiltration for at least another 3 weeks.
Suppression of EBA skin inflammation is abrogated by the
co-injection of a neutralizing IL-10 receptor antibody. Despite
its anti-inflammatory effect, plasmacytosis neither reduces the
numbers of autoreactive COL7-specific plasma cells nor the
autoantibodies that trigger the disease (227). These observations
point toward a significant contribution of pathways that
are involved in the resolution of cutaneous involvement.
Therefore, EBA may manifest not only when many pro-
inflammatory stimuli are present but also when the balance of
pro-inflammatory, anti-inflammatory, and resolving pathways
are unbalanced, driving the cells toward pro-inflammatory
mechanisms.
CD11b is an integrin family member that pairs with CD18 to
form the CR3 heterodimer. CD11b is expressed on the surface
of many leukocytes, including monocytes, neutrophils, natural
killer cells, granulocytes, and macrophages. Unexpectedly, in the
antibody transfer-induced model of EBA, CD11b-deficient mice
develop more severe disease symptoms than wild-type mice in
the late phase of the disease. Furthermore, compared to wild-
type controls, CD11b-deficient mice express increased levels of
circulating IFN-γ and IL-4, suggesting an anti-inflammatory role
for CD11b in the resolution phase of experimental autoimmune
diseases, such as EBA (237).
EMERGING TREATMENTS
The current (unsatisfactory) treatment options for EBA have
been outlined above. An increasing understanding of EBA
pathogenesis indicates new potential therapeutic targets
that interfere in different phases of disease progression,
including the generation of autoantibodies, maintaining
autoantibodies in the circulation, and autoantibody-induced
tissue injury.
Due to the lack of clinical studies, we categorized the emerging
treatments into three categories:
TREATMENTS DESCRIBED IN CASE
REPORTS
Several case reports are known for the treatment of EBA
using ECP (145) and Daclizumab (148). Furthermore, anti-
C1s mAb, a mouse monoclonal IgG2a antibody, inhibits the
activation of C1s, which is a serine protease of the classical
complement system. TNT003 completely blocks complement
classical pathway activation by the reduction of C4a and C5a
production induced by incubation of the sera from patients
with BP on cryosections of human skin (260). The disease
induction of experimental EBA is also complement-dependent.
This finding suggests that TNT003 might work even in EBA. A
“humanized version” of TNT003, TNT009 is currently evaluated
in a phase I clinical trial in BP patients (NCT02502903) and
data reported on congresses indicates a favorable safety, as
well as efficacy in some patients. Sulfasalazine was used in
a patient with EBA associated with Crohn’s disease, resulting
in no improvement of the skin lesion (149). The utility of
doxycycline has been reported in BP (150). Doxycycline and
another tetracycline, minocycline, have been described in the
literature in EBA cases, although their usefulness remains unclear
(151–153).
TREATMENTS APPLIED IN THERAPEUTIC
SETTINGS IN EXPERIMENTAL EBA
Due to the low incidence, clinical studies with EBA patients are
not performed. Therefore, animal models are indispensable for
investigating the pathogenesis of EBA and other autoimmune
blistering diseases and to test new target substances for
treatment; these models include the transfer of autoantibodies
to experimental animals, adoptive transfer of autoantibody-
producing B cells to immune-deficient mice and construction
of transgenic mice that produce autoantibodies (167). Although
animal models have many benefits, as described above, both
the advantages and disadvantages of each model should
be considered. Although the models duplicate the clinical,
histopathological, ultrastructural, and immunological features of
the human disease, these systems are mostly completely murine,
and it is possible that findings in mice will not translate to
humans.
The most important mouse model to test treatments applied
in therapeutic settings is the immunization-induced EBA model
(167, 168). Immunization with parts of the NC1 domain of
COL7 with an adjuvant induces anti-COL7 IgG production
in mice. The susceptibility of experimental EBA is closely
associated with the H2s haplotype in mice (165). During
a time period of 4–6 weeks, the mice develop antibodies
against mCOL7 that bind to the DEJ and induce neutrophil
activation and blistering. Using the immunization-induced
EBA model, the pathomechanisms of blistering and potential
therapeutic options have been studied, and more importantly,
this model is used to test potential new drug candidates and
therapeutics (167). Successfully applied drugs are summarized
in Table 7.
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TABLE 7 | Experimental treatments in pre-clinical immunization-induced EBA.
Medication Target Impact on disease Application References
Methylprednisolone Multiple Impair EBA progression i.p. (129, 212)
DF2156A CXCR1/2 Halting EBA progression p.o. (212)
IVIG Multiple Impair EBA progression i.p. (129)
Anti-GM-CSF GM-CSF Impair EBA progression i.p. (177)
Etanercept TNFα Impair EBA progression i.p. (214)
EndoS Fc glycosylation Halting EBA progression i.p. (192)
sCD32/SM101 FcγR Impair EBA progression i.p (231)
Anakinra IL-1 Improvement i.p. (213)
17-DMAG HSP90 Improvement i.p. (174)
17-AAG HSP90 Impair EBA progression top (242)
TCBL-145 HSP90 Improvement i.p. (174)
Dimethylfumarate Multiple Improvement p.o. (261)
goat anti-mouse IgD serum Induction of IL10 plasma cells Impair EBA progression i.p. (227)
Calcitriol treatment Vitamin D Impair EBA progression p.o. (262)
LAS191954 PI3Kδ Improvement p.o. (239)
Roflumilast PDE4 Halting EBA progression p.o. (240)
CXCR1/2, CXC-chemokin receptor; GM-CSF; granulocyte-macrophage colony-stimulating factor; TNF, tumor necrosis factor; EndoS, endoglycosidase S; FcγR, Fc gamma receptor; IL,
interleukin; 17-DMAG, 17-dimethylaminoethylamino-17-demethoxygeldanamycin; HSP90, heat shock protein 90; 17-AAG, Tanespimycin (17-N-allylamino-17-demethoxygeldanamycin);
TCBL-145, D-Tyr-Phe-D-Trp-Leu-AMB (AMB: NH-CH2-CH2-CH(CH3)2 ); PI3K, phosphoinositide 3-kinase; p.o., per os; i.p., intraperitoneal; top, topical.
TREATMENTS APPLIED IN PREVENTIVE
SETTINGS IN EXPERIMENTAL EBA
Beneath the validation of potential drug candidates in the
therapeutic setting in immunization-induced EBA, some authors
have also investigated several drugs in antibody transfer-induced
EBA. In this model, rabbit sera or whole rabbit IgG immunized
with COL7 NC1 domain are injected into mice. These
mice develop clinical and histological subepidermal blistering
within a few days. The antibody transfer models are used to
investigate the cellular and molecular basis of blistering and
to investigate preventive effects of several therapeutic options.
The use of antibody transfer models enables examination of
the effector phase of EBA. Testing novel drugs or investigating
the pathogenesis of EBA is straightforwardly done because
clinical symptoms are visible days after starting the experiment.
However, similar to most animal models, the situation in human
patients is only partially reflected—mostly, because the signaling
cascade and the interaction of different cell types vary among
human and mice. Additionally, induced disease may last less
than a few days after the transfer of antibodies. Furthermore,
the loss of tolerance and the generation of autoantibodies cannot
be studied in models based on antibody transfer. Therefore,
the investigation of potential drug candidates should always
be performed in addition to immunization-induced EBA in a
therapeutic setting.
Complement
Complement activation has been described as a prerequisite
for blister formation. In the antibody-transfer model, blister
induction is completely dependent on complement C5 because
C5-deficient mice or mice injected with F(ab)2 fragments of
the immune IgGs are devoid of blisters. This finding indicates
that the complement system can be targeted in animal models.
Targeting therapies for complement system factor B, C5, and
C5R ameliorate disease severity in antibody-transfermodels (199,
201, 203, 211, 260). Interestingly, in antibody transfer-induced
BP, C5ar1(−/−) mice are protected from disease development,
whereas the extent of skin lesions is increased in C5ar2(−/−)
animals.
SYK
SYK is a non-receptor cytoplasmic enzyme that is mainly
expressed in hematopoietic cells. SYK regulates cellular responses
to extracellular antigens or antigen-immunoglobulin complexes.
In EBA pathogenesis, myeloid SYK is a central player in driving
inflammation in prototypical autoantibody-transfer models. The
SYK inhibitor (BAY61-3606) protects mice from inflammation in
antibody-transfer EBA (171, 245).
Cell-Derived Nanoparticles (CDNPs)
CDNPs are intercellular protein complexes, such as annexin A1,
annexin A5, actin, 14-3-3ε, 14-3-3ζ, galectin-3, and heat-shock
proteins 27 and 70. CDNPs play a therapeutic role against viral
infections, cancer and in the experimental EBA model. Mice
that receive anti-COL7 IgG develop skin lesions. Treatment
with CDNPs significantly reduces the affected skin lesions and
increases IL-4 expression (263).
LTB4
LTB4 is a potent chemoattractant and activator of myeloid
cells, particularly of neutrophils. The 5-lipoxygenase–deficient
and BLT1-deficient mice exhibit neither any clinical nor
histological signs of disease in the antibody-transfer model.
The 5-lipoxygenase inhibitor (zileuton) targeting the LTB4/BLT1
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pathway ameliorates disease severity by ∼50% in antibody-
transfer models (208).
Flii I
Flii is a member of the gelsolin family of actin remodeling
proteins in regulating cell adhesion and intracellular signaling.
Flii expression is increased in the epidermis during development
and during epidermal stratification tomaintain barrier functions,
such as tight junctions. Topical application of Flii-neutralizing
antibody significantly reduces the clinical severity of blistering
and histological separations in antibody-transfer EBA mice.
In addition, the barrier function measured by transepidermal
water loss (TEWL) is significantly decreased in Flii-neutralizing
antibody-treated mice (218, 219).
IL-6 (Protective)
IL-6 is a proinflammatory cytokine and plays a role during
the transition from innate to acquired immunity. In the initial
immune response to pathogen, IL-6 attracts neutrophils to
the affected tissue. In addition, IL-6 plays a crucial role in
B- and T-cell differentiation. Elevated IL-6 concentrations
are observed in many inflammatory diseases and often
correlate with disease activity. IL-6 expression is increased
in the skin of EBA patients. Interestingly, the EBA severity
is enhanced in IL-6-deficient mice in an experimental
model. Furthermore, treatment with recombinant IL-6 dose-
dependently impairs the induction of experimental EBA
(209).
Galactosylated Immunoglobulins
Antibody-transfer EBA model activation is FcgR-dependent
in blister formation. Immune-complexes induce the classical
complement pathway via Fc fragment. The mouse IgG1 subclass
preferentially binds to inhibitory FcgRIIB and suppresses the
inflammatory response. Glycosylation of Asn297 in the IgG Fc
fragment plays an important role in complement activation.
Highly galactosylated immune-complex treatment reduces the
development of cutaneous lesions in an antibody-transfer model
(202).
CARD9
Caspase recruitment domain-containing protein 9 (CARD9) is
an intracellular adapter protein that is expressed in myeloid-
lineage cells. CARD9 plays a critical role in host defense against
pathogens in both mice and humans. Card9 deficient mice are
significantly protected against skin blistering in antibody-transfer
EBA. In this setting, CARD9 is required for development of
the inflammatory response. These pieces of evidence suggest a
therapeutic target in EBA (246).
Signal Transduction by Scr Kinases
Src family kinases, such as Hck, Fgr, and Lyn, play roles in
malignant transformation and tumor progression, and therefore
they can be targets of cancer therapy. In addition, Src family
kinases are present in many types of immune cells. It is known
that Src family kinases have a role in integrin signal transduction
in neutrophils and macrophages. Hck, Fgr, and Lyn-deficient
mice are completely protected in antibody-transfer EBA (247).
T Cells
Tregs are of importance in modulating host responses to
tumors and infections and in inhibiting the development of
autoimmunity and allergies. T cell-deficient mice are protected
from induction of skin lesions in antibody-transfer EBA.
In particular, specific depletion of Tregs increases disease
progression in antibody transfer-induced EBA. In a similar
experimental setting, NKT-deficient mice and γδT cell-deficient
mice are protected against the induction of experimental EBA
(224, 225).
Signal Transduction by p38, MAPK AKT
In the antibody-transfer model, neutrophils are crucial for
inducing clinical disease. Neutrophil activation is mediated
by the phosphorylation of ERK1/2, p38 MAPK, and
Akt. Methylprednisolone inhibits the phosphorylation of
Akt, ERK1/2, and p38 MAPKs in neutrophils. Chemical
inhibitors of Akt (Akt inhibitor VIII), ERK1/2 (U0126),
and p38 MAPK (SB203580) statistically suppress ex-
vivo dermal-epidermal separation. In addition, ERK1/2
(U0126), and p38 MAPK (SB203580) demonstrate an ∼10%
reduction of disease severity compared with the control
(244).
RORα
RORα is a steroid nuclear hormone receptor and a transcription
factor. Experimental EBA shows strain-dependent disease
severity. To elucidate the strain-dependency, RORα is found to
be a risk gene for the antibody-transfer model. The RORα agonist
SR3335 impairs blister formation in both types of antibody-
transfer EBA (230).
Signal Transduction by PI3Kβ
PI3Ks play major roles in the signaling pathways that link
cell surface receptors to the control of cell function. There
are four defined isoforms of PI3Ks. In particular, PI3Kβ is
widely expressed and blocks arterial thrombus formation. PI3Kβ-
deficient mice are protected from the development of blisters in
the antibody-transfer EBA model.
Others
This antibody-transfer mouse model can be used to validate
or, at least as important exclude novel therapeutic targets in
EBA. For example, TREM1, MIP1a, CD11b, caspase 1/11, and
S100, which are all increasingly expressed in experimental
EBA, have no impact on disease manifestation (213, 221–223,
237).
CONCLUSIONS
Since the first description of EBA over 100 years ago, our
understanding of this serious disease has dramatically improved.
The knowledge of the cellular and molecular mechanisms led
to the development of new therapies, some of which have been
successfully tested in preclinical models and in concept studies in
bullous pemphigoid patients. In the future, new drug targets will
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evolve to improve the treatment and living standards of people
with EBA.
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